您的位置:PharmaNews 行业信息 正文
内容搜索
热门内容
推荐内容
最新内容
反馈意见和建议

WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million(3)
本文章共3847字,分3页,当前第3页,快速翻页:


 


  For more information, please contact:
  WuXi PharmaTech (Cayman) Inc.
  Ronald Aldridge Director of Investor Relations
  Phone: +1-201-585-2048
  Email: ir@wuxiapptec.com

Photo: http://photos.prnewswire.com/prnh/20040705/CNM002LOGO
http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO

Source: WuXi PharmaTech (Cayman) Inc.

CONTACT: WuXi PharmaTech (Cayman) Inc., Ronald Aldridge Director of
Investor Relations, +1-201-585-2048, or ir@wuxiapptec.com
 

Web site: http://www.wuxiapptec.com/
 

转载自pharmaLive


 

 

点这里复制本页地址     发送给您QQ/MSN上的好友


相关文章

VaxGen and diaDexus Complete Merger

WILEX AG recommends shareholders not to

Devax Receives CE Mark for the AXXESS Dr

Employment at NJ Biotechnology Companies

Federal Jury Finds Cornell University's

Conatus Pharmaceuticals Acquires Pfizer'

Charles River Announces Mutual Terminati

USIBC Salutes Abbott Laboratories for 10

药明康德出售搁浅 作价过高或成祸首

全球制药业R&D投入更趋理性

相关评论

    
本文章所属分类:首页 行业信息